{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:07:18Z","timestamp":1778821638746,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jtha.2025.07.033","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T15:41:14Z","timestamp":1755013274000},"page":"3492-3500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetic strategies for achieving precise factor VIII control with susoctocog alfa in acquired hemophilia A"],"prefix":"10.1016","volume":"23","author":[{"given":"Justus","family":"Heeg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"Dobbelstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Iorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heiko","family":"Schenk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Seeliger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3600-8536","authenticated-orcid":false,"given":"Andreas","family":"Tiede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.07.033_bib1","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ajh.24777","article-title":"Acquired hemophilia A: updated review of evidence and treatment guidance","volume":"92","author":"Kruse-Jarres","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2025.07.033_bib2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/hae.14995","article-title":"Acquired bleeding disorders","volume":"30","author":"Tiede","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.07.033_bib3","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1111\/hae.14149","article-title":"The rising incidence of acquired haemophilia A in Germany","volume":"27","author":"Tiede","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.07.033_bib4","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2006-06-029850","article-title":"Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors\u2019 Organisation","volume":"109","author":"Collins","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.07.033_bib5","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1538-7836.2012.04654.x","article-title":"Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)","volume":"10","author":"Knoebl","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.07.033_bib6","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1055\/s-0034-1390004","article-title":"Laboratory diagnosis of acquired hemophilia A: limitations, consequences, and challenges","volume":"40","author":"Tiede","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2025.07.033_bib7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/hematolrep15010003","article-title":"Acquired hemophilia A treated with recombinant porcine factor VIII: case report and literature review on Its efficacy","volume":"15","author":"Borro","year":"2023","journal-title":"Hematol Rep"},{"key":"10.1016\/j.jtha.2025.07.033_bib8","first-page":"279","article-title":"Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01\/2010 study","volume":"136","author":"Holstein","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.07.033_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102337","article-title":"Clot formation and fibrinolysis assays reveal functional differences among hemostatic agents in hemophilia A plasma","volume":"8","author":"Holle","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.07.033_bib10","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1586\/17474086.2015.1040758","article-title":"Recombinant B domain deleted porcine factor VIII for the treatment of bleeding episodes in adults with acquired hemophilia A","volume":"8","author":"Gomperts","year":"2015","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jtha.2025.07.033_bib11","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s40265-016-0576-1","article-title":"Susoctocog alfa: a review in acquired haemophilia A","volume":"76","author":"Burness","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.jtha.2025.07.033_bib12","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/hae.12627","article-title":"Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A","volume":"21","author":"Kruse-Jarres","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.07.033_bib14","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/2040620717720861","article-title":"Review of recombinant anti-haemophilic porcine sequence factor VIII in adults with acquired haemophilia A","volume":"8","author":"Fosbury","year":"2017","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jtha.2025.07.033_bib15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/ijlh.14181","article-title":"Agreement between one stage and chromogenic assays in samples from patients receiving recombinant porcine FVIII (Obizur, susoctocog-alfa)","volume":"46","author":"Guy","year":"2024","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2025.07.033_bib16","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.3390\/diagnostics12081999","article-title":"Analytical performance of different laboratory methods for measuring susoctocog-alfa","volume":"12","author":"Novembrino","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.jtha.2025.07.033_bib17","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/hae.14832","article-title":"Real-world safety and effectiveness of recombinant porcine sequence factor VIII in acquired haemophilia A: a non-interventional, post-authorization safety study","volume":"29","author":"Tarantino","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.07.033_bib18","doi-asserted-by":"crossref","DOI":"10.1177\/20406207241260332","article-title":"Real-world use of recombinant porcine sequence factor VIII in the treatment of acquired hemophilia A: EU PASS","volume":"15","author":"Miesbach","year":"2024","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jtha.2025.07.033_bib19","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/j.1365-2516.2012.02789.x","article-title":"Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A","volume":"18","author":"Kempton","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.07.033_bib20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/hae.13108","article-title":"Recombinant B-domain-deleted porcine sequence factor VIII (r-pFVIII) for the treatment of bleeding in patients with congenital haemophilia A and inhibitors","volume":"23","author":"Mahlangu","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.07.033_bib21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/jth.14618","article-title":"Cross-reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: data from the GTH-AH 01\/2010 Study","volume":"18","author":"Turkantoz","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.07.033_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102553","article-title":"Cross-reacting antiporcine factor VIII inhibitors in patients with acquired hemophilia A","volume":"8","author":"Stephen","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.07.033_bib23","doi-asserted-by":"crossref","first-page":"6240","DOI":"10.1182\/bloodadvances.2020002977","article-title":"Recombinant porcine FVIII for bleed treatment in acquired hemophilia A: findings from a single-center, 18-patient cohort","volume":"4","author":"Ellsworth","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.07.033_bib24","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1046\/j.1365-2141.2000.02226.x","article-title":"Intermittent injections vs. continuous infusion of factor VIII in haemophilia patients undergoing major surgery","volume":"110","author":"Batorova","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.07.033_bib25","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1046\/j.1365-2516.2002.00650.x","article-title":"Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma-derived or recombinant factor VIII concentrates","volume":"8","author":"Dingli","year":"2002","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.07.033_bib26","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/hae.13331","article-title":"Continuous infusion of coagulation factor concentrates during intensive treatment","volume":"24","author":"Holme","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.07.033_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102438","article-title":"Emicizumab as first-line therapy in acquired hemophilia A","volume":"8","author":"Iarossi","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.07.033_bib28","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1055\/a-2197-9738","article-title":"Emicizumab for the treatment of acquired hemophilia a: consensus recommendations from the GTH-AHA Working Group","volume":"44","author":"Pfrepper","year":"2024","journal-title":"Hamostaseologie"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625004969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625004969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:12:11Z","timestamp":1778818331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625004969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1538783625004969"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.07.033","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic strategies for achieving precise factor VIII control with susoctocog alfa in acquired hemophilia A","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.07.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}